Physician profile
Corrie E Smith
NPI 1336927953
$16,665.01
in general payments reported to CMS, 2019-2025
30 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $372 · 2024: $1,825 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $2,997 · Education: $161 · Travel and Lodging: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,367.16 |
| Food and Beverage | $2,997.02 |
| Education | $161.00 |
| Travel and Lodging | $139.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $7,115.43 | 2023-2025 | Erleada, Akeega |
| Janssen Scientific Affairs, LLC | $6,856.45 | 2023-2025 | Erleada, Akeega |
| Medtronic, INC. | $483.66 | 2023-2025 | Interstim, Altaviva |
| Ferring Pharmaceuticals INC. | $306.45 | 2024-2025 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $269.16 | 2023-2025 | |
| Pfizer INC. | $236.16 | 2024-2025 | |
| Axonics, INC. | $197.19 | 2024 | Axonics |
| Procept Biorobotics Corporation | $160.66 | 2024 | Aquabeam System |
| Sumitomo Pharma America, INC. | $107.61 | 2024-2025 | Gemtesa |
| Coloplast Corp | $98.53 | 2023-2025 | Speedicath |
| Novartis Pharmaceuticals Corporation | $86.56 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $83.88 | 2023-2025 | Yonsa |
| Urogen Pharma, INC. | $67.16 | 2024-2025 | |
| Astellas Pharma US INC | $64.56 | 2023-2024 | Xtandi |
| Merck Sharp & Dohme LLC | $62.59 | 2023-2024 | Keytruda, Welireg |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $61.90 | 2024 | Provenge |
| Astrazeneca Pharmaceuticals Lp | $56.45 | 2023-2024 | Lynparza |
| Accord Healthcare, INC. | $47.21 | 2023 | |
| Blue Earth Diagnostics | $39.95 | 2023-2024 | |
| Progenics Pharmaceuticals, INC. | $39.03 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $32.43 | 2023-2025 | Prolaris |
| Tolmar, INC. | $30.01 | 2024 | |
| Calyxo, INC. | $28.81 | 2025 | Cvac Aspiration System |
| Abbott Laboratories | $28.27 | 2024 | Proclaim |
| Integra Lifesciences Corporation | $23.86 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Teleflex LLC | $20.67 | 2025 | Barrigel |
| Cycle Pharmaceuticals INC | $17.47 | 2025 | Venxxiva |
| Olympus America INC. | $15.10 | 2025 | Itind System |
| Immunitybio, INC. | $14.59 | 2025 | |
| Abbvie INC. | $13.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corrie Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.